Andolast, also known as CR-2039, an anti-allergic agent for the treatment of bronchial asthma, chronic obstructive pulmonary disease (COPD). Andolast acts at different cellular levels to inhibit immunoglobulin E synthesis. Andolast proved to be significantly more effective than placebo in improving airflow, and in controlling asthma symptoms both during day and night.